Commentary
See article on page 613HCV in hepatic failure: West and East do not meet
| The first 150 words of the full text of this article appear below. |
Despite the identification of hepatitis C virus (HCV) as
an aetiological agent of blood borne non-A, non-B (NANB) hepatitis a
decade ago, its role in fulminant NANB hepatitis is still
uncertain.1 In the West, HCV is only infrequently
associated with NANB fulminant hepatitis. Thus, in studies from the
USA, positive serum HCV RNA was reported in none of 15 cases by Wright
and colleagues2 and in only two (12%) of 17 cases by
Liang et al.3 Similarly, none
of the 23 and 30 NANB cases in the French and English series, respectively, was positive for HCV infection.4 5 In
contrast, the prevalence of serological markers of HCV infection in
NANB fulminant hepatitis is much higher in the Oriental countries. In
an early study from Japan, Muto et al found
that seven (58%) of 12 patients with NANB fulminant hepatitis were
anti-HCV (anti-C100-3) positive6; findings which were
later confirmed by Yangi et al who reported
Relevant Article
- Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus
- C M Chu, C T Yeh, and Y F Liaw
Gut 1999 45: 613-617.[Abstract] [Full Text] [PDF]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
